Sarah C Mutka

Summary

Publications

  1. pmc ADH IB expression, but not ADH III, is decreased in human lung cancer
    Sarah C Mutka
    N30 Pharmaceuticals, Inc, Boulder, Colorado, United States of America
    PLoS ONE 7:e52995. 2012
  2. pmc Identification of nuclear export inhibitors with potent anticancer activity in vivo
    Sarah C Mutka
    Kosan Biosciences, Inc, Hayward, California 92121, USA
    Cancer Res 69:510-7. 2009
  3. doi request reprint Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities
    Xicheng Sun
    N30 Pharmaceuticals LLC, 3122 Sterling Circle, Suite 200, Boulder, CO 80301, USA
    Bioorg Med Chem Lett 21:5849-53. 2011
  4. doi request reprint Structure-activity relationship of pyrrole based S-nitrosoglutathione reductase inhibitors: carboxamide modification
    Xicheng Sun
    N30 Pharmaceuticals LLC, 3122 Sterling Circle, Boulder, CO 80301, USA
    Bioorg Med Chem Lett 22:2338-42. 2012
  5. doi request reprint Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement
    Xicheng Sun
    N30 Pharmaceuticals LLC, Boulder, CO 80301, USA
    Bioorg Med Chem Lett 21:3671-5. 2011

Collaborators

Detail Information

Publications5

  1. pmc ADH IB expression, but not ADH III, is decreased in human lung cancer
    Sarah C Mutka
    N30 Pharmaceuticals, Inc, Boulder, Colorado, United States of America
    PLoS ONE 7:e52995. 2012
    ..We conclude that the previously reported results showed an incorrect association of GSNOR and human lung cancer risk, and a decrease in ADH IB, rather than GSNOR, correlates with human lung cancer...
  2. pmc Identification of nuclear export inhibitors with potent anticancer activity in vivo
    Sarah C Mutka
    Kosan Biosciences, Inc, Hayward, California 92121, USA
    Cancer Res 69:510-7. 2009
    ..These NEIs show the potential of CRM1 inhibitors as novel and potent anticancer agents...
  3. doi request reprint Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities
    Xicheng Sun
    N30 Pharmaceuticals LLC, 3122 Sterling Circle, Suite 200, Boulder, CO 80301, USA
    Bioorg Med Chem Lett 21:5849-53. 2011
    ..We identified potent and novel GSNOR inhibitors having reduced CYP inhibition activities and demonstrated efficacy in a mouse ovalbumin (OVA) model of asthma...
  4. doi request reprint Structure-activity relationship of pyrrole based S-nitrosoglutathione reductase inhibitors: carboxamide modification
    Xicheng Sun
    N30 Pharmaceuticals LLC, 3122 Sterling Circle, Boulder, CO 80301, USA
    Bioorg Med Chem Lett 22:2338-42. 2012
    ..We have identified potent and novel GSNOR inhibitors that demonstrate efficacy in an ovalbumin (OVA) induced asthma model in mice...
  5. doi request reprint Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement
    Xicheng Sun
    N30 Pharmaceuticals LLC, Boulder, CO 80301, USA
    Bioorg Med Chem Lett 21:3671-5. 2011
    ..We identified equally potent and novel GSNOR inhibitors having pyrrole regioisomers as scaffolds using a structure based approach...